Holen Sie sich die Stockscreener-App
33.23
10.77%
3.23
Schlusskurs vom Vortag:
$30.00
Offen:
$28.9906
24-Stunden-Volumen:
8,851
Relative Volume:
0.22
Marktkapitalisierung:
$33.80M
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$25.13
$33.71
52-Wochen-Spanne:
$25.13
$33.71
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Company Profile
Firmenname
IRulya Therapeutics Inc. Common Stock
Sektor
Branche
Telefon
-
Adresse
-
Compare IRLA vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRLA
IRulya Therapeutics Inc. Common Stock
|
33.23 | 33.80M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-09 | Eingeleitet | Raymond James | Outperform |
| 2026-09-24 | Eingeleitet | Rodman & Renshaw | Buy |
| 2026-09-22 | Hochstufung | Citizens | Mkt Perform → Mkt Outperform |
| 2026-08-20 | Eingeleitet | Craig Hallum | Buy |
| 2026-07-29 | Eingeleitet | Oppenheimer | Outperform |
| 2026-06-24 | Eingeleitet | Leerink Partners | Outperform |
| 2026-06-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-01-30 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-08-05 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-03-24 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
IRulya Therapeutics Inc. Common Stock Aktie (IRLA) Neueste Nachrichten
Quince Therapeutics relaunched as IRulya: Raymond James targeted QNCX stock at USD 72 - ad-hoc-news.de
IRulya Therapeutics Inc. (IRLA) Company Information - Simply Wall Street
IRulya Therapeutics (Nasdaq:IRLA)Stock Analysis - Simply Wall Street
Diluted net income available to common stockholders of IRulya Therapeutics Inc. – NASDAQ:IRLA - TradingView
Quince relaunches as IRulya, going all in on lung disease after Hail Mary merger - Fierce Pharma
Quince Therapeutics rebrands as IRulya, names new CEO - Investing.com
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease - GlobeNewswire
A $116 million cash balance on June 30, 2026, is expected to fund IRulya's operations through 2028. - Stock Titan
Finanzdaten der IRulya Therapeutics Inc. Common Stock-Aktie (IRLA)
Es liegen keine Finanzdaten für IRulya Therapeutics Inc. Common Stock (IRLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):